Susquehanna International Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-210,500
| Closed | -$36.2M | – | 14448 |
|
|
2021
Q3 | $36.2M | Buy |
210,500
+173,700
| +472% | +$22.7M | ﹤0.01% | 1406 |
|
|
2021
Q2 | $4.62M | Sell |
36,800
-12,900
| -26% | -$1.63M | ﹤0.01% | 4173 |
|
|
2021
Q1 | $6.74M | Buy |
49,700
+11,000
| +28% | +$1.42M | ﹤0.01% | 3395 |
|
|
2020
Q4 | $4.95M | Sell |
38,700
-13,900
| -26% | -$1.63M | ﹤0.01% | 3424 |
|
|
2020
Q3 | $5.92M | Sell |
52,600
-65,800
| -56% | -$6.55M | ﹤0.01% | 2834 |
|
|
2020
Q2 | $11.3M | Buy |
118,400
+20,200
| +21% | +$1.95M | ﹤0.01% | 2009 |
|
|
2020
Q1 | $8.82M | Buy |
98,200
+50,300
| +105% | +$3.91M | ﹤0.01% | 1873 |
|
|
2019
Q4 | $2.54M | Sell |
47,900
-61,700
| -56% | -$2.81M | ﹤0.01% | 3943 |
|
|
2019
Q3 | $4.33M | Buy |
109,600
+50,700
| +86% | +$2.2M | ﹤0.01% | 2918 |
|
|
2019
Q2 | $2.42M | Sell |
58,900
-11,600
| -16% | -$480K | ﹤0.01% | 3804 |
|
|
2019
Q1 | $3.28M | Buy |
70,500
+48,000
| +213% | +$2.11M | ﹤0.01% | 3006 |
|
|
2018
Q4 | $980K | Sell |
22,500
-36,500
| -62% | -$1.82M | ﹤0.01% | 4692 |
|
|
2018
Q3 | $3.38M | Sell |
59,000
-114,200
| -66% | -$5.61M | ﹤0.01% | 3195 |
|
|
2018
Q2 | $8.4M | Buy |
173,200
+76,200
| +79% | +$2.78M | ﹤0.01% | 2118 |
|
|
2018
Q1 | $3.79M | Buy |
97,000
+62,500
| +181% | +$2.66M | ﹤0.01% | 2899 |
|
|
2017
Q4 | $1.46M | Sell |
34,500
-22,800
| -40% | -$855K | ﹤0.01% | 4509 |
|
|
2017
Q3 | $2.14M | Sell |
57,300
-12,500
| -18% | -$434K | ﹤0.01% | 3780 |
|
|
2017
Q2 | $2.12M | Buy |
69,800
+15,300
| +28% | +$443K | ﹤0.01% | 3808 |
|
|
2017
Q1 | $1.44M | Sell |
54,500
-900
| -2% | -$23.7K | ﹤0.01% | 4363 |
|
|
2016
Q4 | $1.41M | Sell |
55,400
-500
| -0.9% | -$15.8K | ﹤0.01% | 4790 |
|
|
2016
Q3 | $2.02M | Buy |
55,900
+30,600
| +121% | +$1.01M | ﹤0.01% | 3554 |
|
|
2016
Q2 | $860K | Sell |
25,300
-1,300
| -5% | -$42.3K | ﹤0.01% | 5163 |
|
|
2016
Q1 | $702K | Sell |
26,600
-97,700
| -79% | -$2.84M | ﹤0.01% | 5792 |
|
|
2015
Q4 | $6.06M | Sell |
124,300
-25,600
| -17% | -$921K | ﹤0.01% | 2286 |
|
|
2015
Q3 | $3.73M | Buy |
149,900
+47,100
| +46% | +$1.42M | ﹤0.01% | 3120 |
|
|
2015
Q2 | $3.25M | Buy |
102,800
+42,200
| +70% | +$1.36M | ﹤0.01% | 3695 |
|
|
2015
Q1 | $2.31M | Buy |
60,600
+29,700
| +96% | +$1.18M | ﹤0.01% | 4044 |
|
|
2014
Q4 | $1.2M | Buy |
30,900
+9,000
| +41% | +$314K | ﹤0.01% | 5487 |
|
|
2014
Q3 | $662K | Buy |
21,900
+14,700
| +204% | +$414K | ﹤0.01% | 6698 |
|
|
2014
Q2 | $245K | Buy |
+7,200
| New | +$241K | ﹤0.01% | 8722 |
|
Susquehanna International Group's XLRN Position: Q4 2021 in Review
Susquehanna International Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 384,210 shares — an estimated $66.1M sold.
Susquehanna International Group first reported a position in XLRN in Q2 2014 and held it in 17 quarters. The position peaked at $66.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Susquehanna International Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Susquehanna International Group sold 384,210 Acceleron Pharma shares in Q4 2021, an estimated $66.1M.
- Susquehanna International Group first reported a position in Acceleron Pharma in Q2 2014 and held it in 17 quarters.
- Susquehanna International Group's Acceleron Pharma position peaked at $66.1M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.